Hydroxychloroquine - The sanjeevani for Indian Pharma Industry

4 hrs


Where our thinking ends, the actual plan starts to unfold.

Majority of us i.e. common people are impulsive in nature and react at the drop of a hat. How dare President Trump has threatened India of a ‘retaliation’ if we don’t give Hydroxychloroquine and why was Modi Ji so soft in dealing with that, we bowed down before the threat and what not.

First of all, when a reporter asks what are you going to do if India doesn’t accept your request of sending mute drug, what do you expect the head of world’s most powerful country to say - “we’ll retaliate” is a good enough answer. It’s not a threat of a war, a trade restriction at best even if it means anything.

Now comes the part why India agreed to provide the drug thereafter. India took a good 2-3 days before agreeing to provide the drug to USA. What happened in these 2-3 days is the part which majority of Indians haven't noticed at all. What people couldn't see was the sudden change of USFDA towards Indian pharmaceutical companies.


Till the end of Feb 2020, Indian companies were issued warning letters and the business was suffering. Needless to mention, the pharmaceutical industry was worried as the business from the US market, currently valued at close to $ 3,00,000 Million was under serious threat.

So what has happened after India approved export of Hydroxychloroquine?

Coincidentally, four major manufacturing plants of Indian pharmaceutical companies were approved. Coincidentally, the USFDA lifted a three years old ban from an Indian pharmaceutical company.


Too many coincidences at once is never a coincidence. This is how international diplomacy works, you’ve to think how to make the best use of a situation irrespective of whether it’s your planned one or an imposed one.

Just like in Ramayana, where Sanjeevani Booti helped Laxman ji to regain consciousness and thus contributed to the defeat of Ravaan, Hydroxychloroquine has surely helped the Indian Pharmaceutical industry to regain its share in the US market.  

Comments